* MEDESIS PHARMA *
2003 - Midi-Pyrénées
Baillargues
(near Montpellier)
www.medesispharma.com Discovery, Drugs
Key words: Nanotechnology drug delivery systems, Metals low doses, Vanadium, Manganese, Strontium, Metabolic syndrome, Diabetes
Mission: to develop new innovative treatments of diabetes and neurodegenerative disorders based on metallic ions technology
Clients: undisclosed
contact@medesispharma.com
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.: Maurel (Jean-Claude) [founder, born 1946, M.D., M.Sc., ex-Natura Medica (founder)]
Sc.Dir.:
Oper.Dir.: Cudenec (Claude-Alain) [Ph.D., ex-Servier, Pierre Fabre]
Fin.Dir.:
BusDev: Jackson (Peter)
Financers: privately owned | Turnover (M€) : 0.085 (2007)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Preclin
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2008 .04 | Financing (no interest loan) : 0.9 M€, by OSEO and Languedoc-Roussillon region, to support its ongoing program for NP01 in diabetes | DEBT | [5 years] |
| 2008 .01 | Company move from Paris to Baillargues (10km from Montpellier) | ORGL | [5 years] |
| 2006 .01 | Clinical trial planned, after first preclinical trial results on NP01 on metabolic syndrome | CLIN | [3 years] |
| 2003 .04 | Company founded by Jean-Claude Maurel, headquartered in Baillargues (today : labs location) | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
